他达拉非联合坦索罗辛治疗FPKRP术后继发阴茎勃起功能障碍的临床观察  

Clinical Observation of Tadalafil Combined with Tamsulosin in the Treatment of ED Patients after FPKRP

作　　者：林升汉 黄卫[2] 孙占玉 李猛[1] LIN Shenghan HUANG Wei SUN Zhanyu LI Meng(Dept. of Urology, Danzhou First People＇s Hospital, Hainan Danzhou 571700, China Dept. of Urology, Hainan Provincial People＇ s Hospital, Haikou 570100, China)

机构地区：[1]儋州市第一人民医院泌尿外科,海南儋州571700 [2]海南省人民医院泌尿外科,海口570100

出　　处：《中国药房》2017年第21期2944-2947,共4页China Pharmacy

摘　　要：目的:观察他达拉非联合坦索罗辛治疗经尿道四区分割法双极等离子体前列腺剜切术(FPKRP)后继发阴茎勃起功能障碍(ED)的疗效和安全性。方法:70例FPKRP术后继发ED患者随机分为对照组和观察组,每组35例。两组患者均行常规FPKRP术治疗,术后1 d对照组患者给予盐酸坦索罗辛缓释胶囊0.2 mg,口服,每天1次;观察组患者在对照组治疗基础上加服他达拉非片10 mg,每天1次。两组疗程均为3个月。观察并比较两组患者临床疗效,治疗前后国际前列腺症状评分、前列腺特异抗原、最大尿流率、国际勃起功能问卷-5评分、生活质量指数评分和不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(97.14%vs.71.43%,P<0.05)。治疗前,两组患者国际前列腺症状评分、最大尿流率、国际勃起功能问卷-5评分和生活质量指数评分比较,差异均无统计学意义(P>0.05);治疗后,两组患者国际前列腺症状评分和生活质量指数评分显著低于同组治疗前,且观察组显著低于对照组;最大尿流率和国际勃起功能问卷-5评分显著高于同组治疗前,且观察组显著高于对照组,差异均有统计学意义(P<0.05)。两组患者治疗前后前列腺特异抗原水平比较,差异无统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P<0.05)。结论:他达拉非联合坦索罗辛治疗FPKRP术后继发ED疗效较好,可有效改善患者阴茎勃起功能,缓解下尿路症状,提高日常生活质量,安全性亦较好。OBJECTIVE： To observe the efficacy and safety of tadalafil combined with tamsulosin in the treatment of erectile dysfunction（ED） patients after four area division plasmakinetic enucleation of prostate （FPKRP）. METHODS： Seventy patients with ED after FPKRP were randomly divided into control group and observation group, with 35 cases in each group. Both groups received FPKRP; control group was given Tamsulosin capsule 0.2 mg orally, once a day,1 d after surgery; observation group was additionally given Tadalafil tablet 10 mg, once a day, on the basis of control group. Both groups were treated for 3 months. Clinical efficacies of 2 groups were compared; international prostate symptom score, the levels of prostate specific antigen, the maximal urinary flow rate, international erectile function questionnaire-5 score, life quality score and ADR were also compared before and after treatment. RESULTS： The total response rate of short-term therapy in observation group was significantly better than control group, with statistical significance（97.14% vs. 71.43%, P〈0.05）. Before treatment, there was no significant difference between 2 groups in terms of international prostate symptom score, the maximal urinary flow rate, international erectile function questionnaire-5 score and life quality score （P〉0.05）. After treatment, international prostate symptom score and life quality score in 2 groups were significantly lower than before treatment, and the observation group was significantly lower than the control group; the maximal urinary flow rate and international erectile function questionnaire-5 score were significantly higher than before treatment, and the observation group was significantly higher than the control group, with statistical significance （P〈0.05）. There was no statistical significance in the levels of prostate specific antigen between 2 groups before and after treatment （P〈0.05）. There was no statistical significance in the incidence of ADR between 2 groups（P〉0.05）. CO

关 键 词：他达拉非 坦索罗辛 经尿道四区分割法双极等离子体前列腺剜切术 勃起功能障碍 疗效 安全性 

分 类 号：R699.2[医药卫生—泌尿科学]